Investors

Building shareholder value through innovation in autoimmune, fibrotic, and oncological disease.

Overview

Liferna is advancing a diversified portfolio of therapies designed to transform outcomes for patients with autoimmune, fibrotic, and other serious diseases. The company is developing innovative RNA therapeutics, monoclonal antibodies, cell therapies, and small molecules targeting key disease pathways.

Guided by deep scientific insight and a capital-efficient development model, Liferna is committed to accelerating the delivery of meaningful, life-changing therapies to patients worldwide.

To learn more about Liferna, visit Liferna.com and follow us on X (Twitter), LinkedIn and Instagram.

NASDAQ: LFRN

$22.43

As of May 4, 2026 12:18 PM EDT

Investor Resources

Press Releases

Latest corporate announcements and press releases.

Events

Upcoming investor events, conferences, and webcasts.

Corporate Presentations

Investor presentations and corporate slides.

Financial Reports

Quarterly and annual financial reports.

Governance & Compliance

Corporate Governance

Board of directors, committees, and governance documents.

SEC Filings & Resources

SEC filings, prospectuses, and investor resources.

Get in Touch

Investor Contact

For investor inquiries, please contact our investor relations team.

Media Contact

For media and press inquiries, please reach out to our communications team.